BioCentury | Jun 6, 2020
Finance

Sale of up to 19 Woodford stakes chips away at firm’s remaining portfolio

...round and $100 million series C round; a $107 million offering for stem cell play ReNeuron Group plc...
BioCentury | Feb 10, 2020
Finance

Woodford pain continues as report suggests deal to sell private biotech stakes falls through

...$151.5 Autolus Therapeutics plc (NASDAQ:AUTL) $135.5 Mereo BioPharma Group plc (LSE:MPH; NASDAQ:MREO) $118.6 BenevolentAI $115.0 ReNeuron Group plc...
BioCentury | Oct 19, 2019
Finance

Woodford’s empire crumbles. U.K biotech stays standing

...$151.5 Autolus Therapeutics plc (NASDAQ:AUTL) $135.5 Mereo BioPharma Group plc (LSE:MPH; NASDAQ:MREO) $118.6 BenevolentAI $115.0 ReNeuron Group plc...
...round and $100 million series C round; a $107 million offering for stem cell play ReNeuron Group plc...
BioCentury | Oct 15, 2019
Financial News

Woodford flagship fund implodes as star fund manager axed

...round and $100 million series C round; a $107 million offering for stem cell play ReNeuron Group plc...
BioCentury | Aug 14, 2019
Company News

Aug. 14 Company Quick Takes: Myriad plunges on sales concerns; plus AbbVie-Allergan, TB Alliance, Akari, Carmine

...for the product in 4Q19. ReNeuron partners with U of Cardiff for delivery systems research ReNeuron Group plc...
...systems that can transport therapeutic nucleic acids, such as siRNA, across the blood-brain barrier using ReNeuron’s...
...from an investor consortium led by Esco. BioCentury Staff pretomanid, nitroimidazopyran (PA-824) AbbVie Inc. Akari Therapeutics plc Allergan plc Myriad Genetics Inc. ReNeuron Group plc TB...
BioCentury | Apr 9, 2019
Company News

Fosun gains pair of cell therapies from ReNeuron

...exclusive rights to develop and commercialize its hRPC and CTX stem cell therapies in China. ReNeuron Group plc...
...up front and is eligible for estimated milestones of $104.8 million, plus 12-14% tiered royalties. ReNeuron...
...progenitor cells. The therapy is in a U.S. Phase I/II trial to treat retinitis pigmentosa. ReNeuron's...
BioCentury | Mar 22, 2019
Product Development

Regulating regeneration in Europe

...the designations are also eligible for accelerated approval. Shaun Stapleton, head of regulatory affairs at ReNeuron Group plc...
...has RMAT designation in the U.S., where it is in Phase III testing for angina. ReNeuron’s...
...Celixir plc, Stratford-upon-Avon, U.K. European Medicines Agency (EMA), Amsterdam, Netherlands Nipro Corp. (JASDAQ:8086), Osaka, Japan ReNeuron Group plc...
BioCentury | Feb 22, 2019
Clinical News

ReNeuron's hRPC stem cells improve vision in first cohort of retinitis pigmentosa patients

...I portion who had extensive retinal damage, very poor vision and lacked potential for improvement. ReNeuron...
...the U.S. and EU and Fast Track designation in the U.S. to treat retinitis pigmentosa. ReNeuron Group plc...
...acuity Status: Preliminary Phase II data Milestone: Additional Phase II data (mid-2019) Brian Moy HRPC stem cells (ren003) ReNeuron Group plc Retinitis...
BioCentury | Oct 4, 2018
Emerging Company Profile

Banking on exosomes

...to BioCentury’s BCIQ database, at least two other companies are exploring exosome-based therapies for cancer. ReNeuron Group plc...
...development for cancer. The therapy consists of exosomes derived from immortalized human neural stem cells. ReNeuron...
...cells in clinical testing for stroke and ischemia/reperfusion injury. Randolph Corteling, head of research at ReNeuron...
BioCentury | Apr 10, 2018
Company News

Management tracks: Immunomedics, argenx

...Cambridge, U.K.). Commense is developing microbiome-based therapeutics for pediatric and maternal health. Cell therapy company ReNeuron Group plc...
Items per page:
1 - 10 of 166
BioCentury | Jun 6, 2020
Finance

Sale of up to 19 Woodford stakes chips away at firm’s remaining portfolio

...round and $100 million series C round; a $107 million offering for stem cell play ReNeuron Group plc...
BioCentury | Feb 10, 2020
Finance

Woodford pain continues as report suggests deal to sell private biotech stakes falls through

...$151.5 Autolus Therapeutics plc (NASDAQ:AUTL) $135.5 Mereo BioPharma Group plc (LSE:MPH; NASDAQ:MREO) $118.6 BenevolentAI $115.0 ReNeuron Group plc...
BioCentury | Oct 19, 2019
Finance

Woodford’s empire crumbles. U.K biotech stays standing

...$151.5 Autolus Therapeutics plc (NASDAQ:AUTL) $135.5 Mereo BioPharma Group plc (LSE:MPH; NASDAQ:MREO) $118.6 BenevolentAI $115.0 ReNeuron Group plc...
...round and $100 million series C round; a $107 million offering for stem cell play ReNeuron Group plc...
BioCentury | Oct 15, 2019
Financial News

Woodford flagship fund implodes as star fund manager axed

...round and $100 million series C round; a $107 million offering for stem cell play ReNeuron Group plc...
BioCentury | Aug 14, 2019
Company News

Aug. 14 Company Quick Takes: Myriad plunges on sales concerns; plus AbbVie-Allergan, TB Alliance, Akari, Carmine

...for the product in 4Q19. ReNeuron partners with U of Cardiff for delivery systems research ReNeuron Group plc...
...systems that can transport therapeutic nucleic acids, such as siRNA, across the blood-brain barrier using ReNeuron’s...
...from an investor consortium led by Esco. BioCentury Staff pretomanid, nitroimidazopyran (PA-824) AbbVie Inc. Akari Therapeutics plc Allergan plc Myriad Genetics Inc. ReNeuron Group plc TB...
BioCentury | Apr 9, 2019
Company News

Fosun gains pair of cell therapies from ReNeuron

...exclusive rights to develop and commercialize its hRPC and CTX stem cell therapies in China. ReNeuron Group plc...
...up front and is eligible for estimated milestones of $104.8 million, plus 12-14% tiered royalties. ReNeuron...
...progenitor cells. The therapy is in a U.S. Phase I/II trial to treat retinitis pigmentosa. ReNeuron's...
BioCentury | Mar 22, 2019
Product Development

Regulating regeneration in Europe

...the designations are also eligible for accelerated approval. Shaun Stapleton, head of regulatory affairs at ReNeuron Group plc...
...has RMAT designation in the U.S., where it is in Phase III testing for angina. ReNeuron’s...
...Celixir plc, Stratford-upon-Avon, U.K. European Medicines Agency (EMA), Amsterdam, Netherlands Nipro Corp. (JASDAQ:8086), Osaka, Japan ReNeuron Group plc...
BioCentury | Feb 22, 2019
Clinical News

ReNeuron's hRPC stem cells improve vision in first cohort of retinitis pigmentosa patients

...I portion who had extensive retinal damage, very poor vision and lacked potential for improvement. ReNeuron...
...the U.S. and EU and Fast Track designation in the U.S. to treat retinitis pigmentosa. ReNeuron Group plc...
...acuity Status: Preliminary Phase II data Milestone: Additional Phase II data (mid-2019) Brian Moy HRPC stem cells (ren003) ReNeuron Group plc Retinitis...
BioCentury | Oct 4, 2018
Emerging Company Profile

Banking on exosomes

...to BioCentury’s BCIQ database, at least two other companies are exploring exosome-based therapies for cancer. ReNeuron Group plc...
...development for cancer. The therapy consists of exosomes derived from immortalized human neural stem cells. ReNeuron...
...cells in clinical testing for stroke and ischemia/reperfusion injury. Randolph Corteling, head of research at ReNeuron...
BioCentury | Apr 10, 2018
Company News

Management tracks: Immunomedics, argenx

...Cambridge, U.K.). Commense is developing microbiome-based therapeutics for pediatric and maternal health. Cell therapy company ReNeuron Group plc...
Items per page:
1 - 10 of 166